U.S. flag

An official website of the United States government

NM_015836.4(WARS2):c.37T>G (p.Trp13Gly) AND Neurodevelopmental disorder, mitochondrial, with abnormal movements and lactic acidosis, with or without seizures

Germline classification:
Conflicting interpretations of pathogenicity (6 submissions)
Last evaluated:
May 5, 2022
Review status:
criteria provided, conflicting classifications
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV000509078.18

Allele description [Variation Report for NM_015836.4(WARS2):c.37T>G (p.Trp13Gly)]

NM_015836.4(WARS2):c.37T>G (p.Trp13Gly)

Genes:
LOC129931299:ATAC-STARR-seq lymphoblastoid active region 1590 [Gene]
WARS2-AS1:WARS2 antisense RNA 1 [Gene - HGNC]
WARS2:tryptophanyl tRNA synthetase 2, mitochondrial [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
1p12
Genomic location:
Preferred name:
NM_015836.4(WARS2):c.37T>G (p.Trp13Gly)
Other names:
p.W13G
HGVS:
  • NC_000001.11:g.119140608A>C
  • NG_050658.1:g.5181T>G
  • NM_001378226.1:c.-118T>G
  • NM_001378227.1:c.-309T>G
  • NM_001378228.1:c.37T>G
  • NM_001378229.1:c.37T>G
  • NM_001378230.1:c.-437T>G
  • NM_001378231.1:c.37T>G
  • NM_015836.4:c.37T>GMANE SELECT
  • NM_201263.2:c.37T>G
  • NP_001365157.1:p.Trp13Gly
  • NP_001365158.1:p.Trp13Gly
  • NP_001365160.1:p.Trp13Gly
  • NP_056651.1:p.Trp13Gly
  • NP_056651.1:p.Trp13Gly
  • NP_957715.1:p.Trp13Gly
  • NC_000001.10:g.119683231A>C
  • NC_000001.10:g.119683231A>C
  • NM_015836.3(WARS2):c.37T>G
  • NM_015836.3:c.37T>G
  • NM_015836.4:c.37T>G
  • NR_125974.1:n.213A>C
  • NR_125975.1:n.213A>C
  • NR_125976.1:n.213A>C
  • NR_125977.1:n.213A>C
  • p.Trp13Gly
Protein change:
W13G; TRP13GLY
Links:
OMIM: 604733.0002; dbSNP: rs139548132
NCBI 1000 Genomes Browser:
rs139548132
Molecular consequence:
  • NM_001378226.1:c.-118T>G - 5 prime UTR variant - [Sequence Ontology: SO:0001623]
  • NM_001378227.1:c.-309T>G - 5 prime UTR variant - [Sequence Ontology: SO:0001623]
  • NM_001378230.1:c.-437T>G - 5 prime UTR variant - [Sequence Ontology: SO:0001623]
  • NM_001378228.1:c.37T>G - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001378229.1:c.37T>G - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001378231.1:c.37T>G - missense variant - [Sequence Ontology: SO:0001583]
  • NM_015836.4:c.37T>G - missense variant - [Sequence Ontology: SO:0001583]
  • NM_201263.2:c.37T>G - missense variant - [Sequence Ontology: SO:0001583]
  • NR_125974.1:n.213A>C - non-coding transcript variant - [Sequence Ontology: SO:0001619]
  • NR_125975.1:n.213A>C - non-coding transcript variant - [Sequence Ontology: SO:0001619]
  • NR_125976.1:n.213A>C - non-coding transcript variant - [Sequence Ontology: SO:0001619]
  • NR_125977.1:n.213A>C - non-coding transcript variant - [Sequence Ontology: SO:0001619]
Observations:
6

Condition(s)

Name:
Neurodevelopmental disorder, mitochondrial, with abnormal movements and lactic acidosis, with or without seizures
Identifiers:
MONDO: MONDO:0060578; MedGen: C4540192; OMIM: 617710

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV000606854OMIM
no assertion criteria provided
Pathogenic
(Feb 18, 2022)
germlineliterature only

PubMed (4)
[See all records that cite these PMIDs]

SCV001142303Reproductive Health Research and Development, BGI Genomics
no assertion criteria provided
Likely pathogenic
(Jan 6, 2020)
germlinecuration

SCV001150306Institute of Human Genetics Munich, Klinikum Rechts Der Isar, TU München
criteria provided, single submitter

(Classification criteria August 2017)
Pathogenic
(Feb 28, 2020)
maternal, paternal, germlineclinical testing

Citation Link,

SCV001445976Broad Center for Mendelian Genomics, Broad Institute of MIT and Harvard
criteria provided, single submitter

(ACMG Guidelines, 2015)
Uncertain significance
(Nov 16, 2020)
germlinecuration

PubMed (6)
[See all records that cite these PMIDs]

SCV002519963Mendelics
criteria provided, single submitter

(Mendelics Assertion Criteria 2019)
Pathogenic
(May 4, 2022)
germlineclinical testing

Citation Link,

SCV003835652Baylor Genetics
criteria provided, single submitter

(ACMG Guidelines, 2015)
Uncertain significance
(May 5, 2022)
unknownclinical testing

PubMed (1)
[See all records that cite this PMID]

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineyes2not providednot provided2not providedclinical testing
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing, curation
not providedpaternalyes3not providednot provided3not providedclinical testing
not providedgermlinenot providednot providednot providednot providednot providednot providedliterature only
not providedmaternalyes1not providednot provided1not providedclinical testing
not providedunknownunknownnot providednot providednot providednot providednot providedclinical testing

Citations

PubMed

WARS2 mutations cause dopa-responsive early-onset parkinsonism and progressive myoclonus ataxia.

Skorvanek M, Rektorova I, Mandemakers W, Wagner M, Steinfeld R, Orec L, Han V, Pavelekova P, Lackova A, Kulcsarova K, Ostrozovicova M, Gdovinova Z, Plecko B, Brunet T, Berutti R, Kuipers DJS, Boumeester V, Havrankova P, Tijssen MAJ, Kaiyrzhanov R, Rizig M, Houlden H, et al.

Parkinsonism Relat Disord. 2022 Jan;94:54-61. doi: 10.1016/j.parkreldis.2021.11.030. Epub 2021 Dec 2.

PubMed [citation]
PMID:
34890876

Targeted next generation sequencing identifies novel pathogenic variants and provides molecular diagnoses in a cohort of pediatric and adult patients with unexplained mitochondrial dysfunction.

Nogueira C, Silva L, Pereira C, Vieira L, Leão Teles E, Rodrigues E, Campos T, Janeiro P, Gaspar A, Dupont J, Bandeira A, Martins E, Magalhães M, Sequeira S, Vieira JP, Santos H, Vilarinho S, Vilarinho L.

Mitochondrion. 2019 Jul;47:309-317. doi: 10.1016/j.mito.2019.02.006. Epub 2019 Mar 1.

PubMed [citation]
PMID:
30831263
See all PubMed Citations (7)

Details of each submission

From OMIM, SCV000606854.2

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedliterature only PubMed (4)

Description

Mitochondrial Neurodevelopmental Disorder with Abnormal Movements and Lactic Acidosis and without Seizures

For discussion of the c.37T-G transversion (c.37T-G, NM_201263.2) in the WARS2 gene, resulting in a trp13-to-gly (W13G) substitution, that was found in compound heterozygous state in 2 sisters with mitochondrial neurodevelopmental disorder with abnormal movements and lactic acidosis and without seizures (NEMMLAS; 617710) by Musante et al. (2017), see 604733.0001.

Childhood-Onset Parkinsonism-Dystonia 3

In a 17-year-old boy with childhood-onset parkinsonism-dystonia-3 (PKDYS3; 619738), Burke et al. (2018) identified compound heterozygous missense mutations in the WARS2 gene: a W13G substitution in exon 1, affecting the mitochondrial localization signal, and a c.683C-G transversion in exon 6, resulting in a ser228-to-trp (S228W; 604733.0008) substitution in the tryptophan-tRNA ligase domain. The mutations, which were found by exome sequencing and confirmed by Sanger sequencing, segregated with the disorder in the family. W13G was present in the ExAC database with an allelic frequency of 0.0034 and was not predicted to be extremely deleterious, whereas S228W was not present in ExAC. Western blot analysis of patient cells showed a marked decrease in steady-state levels of WARS2 compared to controls. Patient skeletal muscle biopsy showed mild mitochondrial abnormalities, although OXPHOS activity was normal; the authors postulated that mitochondrial dysfunction contributed to nigrostriatal degeneration. The patient had onset of levodopa-responsive parkinsonism at about 2 years of age; the disorder was progressive.

In a 31-year-old man with PKDYS3, Hubers et al. (2019) identified compound heterozygous missense mutations in the WARS2 gene: W13G and a c.149G-A transition, resulting in a gly50-to-asp (G50D; 604733.0009) substitution. The mutations, which were found by trio-based exome sequencing, segregated with the disorder in the family. W13G was found 9 times in the homozygous state in the gnomAD database, consistent with it being a hypomorphic allele and only disease-causing when combined with a more deleterious allele. G50D was not present in gnomAD. Functional studies of the variants and studies of patient cells were not performed. The patient developed a severe hyperkinetic movement disorder in the first years of life; he also had cognitive defects and could communicate nonverbally on a basic level. Brain imaging showed cerebellar atrophy. He did not have seizures, which may have explained his long survival.

In 6 patients from 4 unrelated families with PKDYS3, Skorvanek et al. (2022) identified compound heterozygous mutations in the WARS2 gene. All patients carried a W13G variant on 1 allele. Two sibs from family 1 had a deletion of exon 2 on the other allele (604733.0011). Fibroblasts derived from these patients showed decreased levels of full-length WARS2 protein compared to controls. Two sibs from family 2 carried leu100del (604733.0004) on the other allele; functional studies were not performed. The patient from family 3 carried G50D (604733.0009) on the other allele; functional studies were not performed. The patient from family 4 carried a c.622G-T transversion, resulting in a glu208-to-ter (E208X; 604733.0012) substitution on the other allele; functional studies were not performed, but it was predicted to result in premature termination.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlinenot providednot providednot providednot providednot providednot providednot providednot provided

From Reproductive Health Research and Development, BGI Genomics, SCV001142303.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedcurationnot provided

Description

NM_015836.3:c.37T>G in the WARS2 gene has an allele frequency of 0.006 in other subpopulation in the gnomAD database. Functional studies demonstrate that c.37T>G has affected a mitochondrial signal peptide (SP) leading to mislocalization of the mutant protein in the cells (PMID: 28236339). It was detected in individual with autosomal recessive Neurodevelopmental disorder, mitochondrial, with abnormal movements and lactic acidosis, with or without seizures, compound heterozygous with c.325delA (PMID: 28236339). Benign computational verdict because benign predictions from DANN, DEOGEN2, EIGEN, FATHMM-MKL, M-CAP, MVP, MutationTaster, PrimateAI, REVEL and SIFT. Taken together, we interprete this variant as Pathogenic/Likely pathogenic variant. ACMG/AMP criteria applied: PS3; PM3; BP4.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

From Institute of Human Genetics Munich, Klinikum Rechts Der Isar, TU München, SCV001150306.2

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not provided1not providednot providedclinical testingnot provided
2not provided1not providednot providedclinical testingnot provided
3not provided1not providednot providedclinical testingnot provided
4not provided1not providednot providedclinical testingnot provided
5not provided1not providednot providedclinical testingnot provided
6not provided1not providednot providedclinical testingnot provided
#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1paternalyes1bloodnot provided1not providednot providednot provided
2paternalyes1bloodnot provided1not providednot providednot provided
3germlineyes1bloodnot provided1not providednot providednot provided
4maternalyes1bloodnot provided1not providednot providednot provided
5paternalyes1bloodnot provided1not providednot providednot provided
6germlineyes1bloodnot provided1not providednot providednot provided

From Broad Center for Mendelian Genomics, Broad Institute of MIT and Harvard, SCV001445976.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedcuration PubMed (6)

Description

The heterozygous p.Trp13Gly variant in WARS2 was identified by our study in the compound heterozygous state, along with another variant of unknown significance, in 1 individual with neurodevelopmental disorder, mitochondrial, with abnormal movements and lactic acidosis, with or without seizures. The variant has been reported in at least 7 individuals, of varied ethnicities, with neurodevelopmental disorder, mitochondrial, with abnormal movements and lactic acidosis, with or without seizures (PMID: 29120065, 28236339, 32120303, 30831263, 31970218). This variant has been identified in 0.46% (590/128958) of European non-Finnish chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP ID: rs139548132) and was detected in homozygosity in 6 control individuals from various populations, suggesting that this variant is not pathogenic for neurodevelopmental disorder, mitochondrial, with abnormal movements and lactic acidosis, with or without seizures. This variant has also been reported in ClinVar (Variation ID: 440915) as likely benign by Invitae, pathogenic by OMIM and Institute of Human Genetics, Klinikum rechts der Isar, likely pathogenic by Reproductive Health Research and Development, BGI Genomics, and as having unknown significance by CeGaT Praxis fuer Humangenetik Tuebingen. Of the 7 affected individuals, 2 were compound heterozygotes that carried a reported likely pathogenic variants in trans and 2 were compound heterozygotes that carried variants of uncertain significance in trans which increases the likelihood that the p.Trp13Gly variant is pathogenic (Variation ID: 440914, 807717; PMID: 29120065, 28236339, 32120303, 30831263, 31970218). In vitro functional studies provide some evidence that the variant may impact protein function (PMID: 29120065, PMID: 28236339). However, these types of assays may not accurately represent biological function. Computational prediction tools, including splice predictors, and conservation analyses suggest that this variant may not impact the protein. In summary, while the clinical significance of the p.Trp13Gly variant is uncertain, these data suggest that it is more likely to be benign. ACMG/AMP Criteria applied: BS1, BS2, PS3_moderate, PM3, BP4 (Richards 2015).

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

From Mendelics, SCV002519963.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testingnot provided
#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

From Baylor Genetics, SCV003835652.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (1)
#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1unknownunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Nov 3, 2024